PERITONEAL CANCER

This study looks at whether giving chemotherapy before and after surgery (plus heated chemotherapy inside the abdomen) helps people with colorectal cancer that has spread to the lining of the belly live longer compared to having surgery alone. About 358 adults with resectable tum…

This study tested a combination of three drugs (nivolumab, bevacizumab, and rucaparib) in 72 people whose ovarian, fallopian tube, or peritoneal cancer had returned after standard treatment. The goal was to see if the combination could shrink tumors or slow cancer growth. While t…

This study tests whether adding oregovomab to niraparib can help control platinum-sensitive recurrent ovarian cancer. Ten adults with this type of cancer will receive both drugs. The goal is to see if the combination shrinks tumors or stops them from growing, while monitoring sid…

This study tests whether adding the immunotherapy drug oregovomab to standard chemotherapy can help people with advanced ovarian cancer live longer without their cancer growing. About 615 newly diagnosed patients who had surgery to remove most of their cancer will receive either …

This early-stage study tests an experimental drug called BL-M17D1 in 120 adults with advanced solid tumors that have a specific protein (HER2) or a HER2 gene change. The main goals are to check the drug's safety, find the right dose, and see if it shrinks tumors. Participants mus…

This study looks at a fast way to identify depression in women with ovarian, peritoneal, or fallopian tube cancer. It also compares a special support program with enhanced standard care to see which better improves quality of life. About 409 women on active treatment took part. T…

This study tests whether a reminder sent to doctors can increase the number of women with suspicious ovarian masses who are referred to a gynecologic oncologist within 30 days. The study includes 20 women aged 18 and older with a suspicious mass found on imaging. Researchers will…